GGrantIndex
← Leaderboards

Karen K Miller

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$23,499,917
Attributed
$30,020,564
Total exposure
20
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$30,020,564 · 20

By mechanism

R01$11,251,152 · 4
T32$7,766,568 · 1
K12$4,859,400 · 1
M01$2,010,511 · 10
K24$1,603,145 · 1
R24$1,573,788 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Woman”

Research focus

WomanDoseClinical ResearchFatty Acid Glycerol EstersObesityBody CompositionResearch PersonnelEndocrinologyLipidsFemaleSomatotropinThickHuman SubjectLipoproteinsAbdominal FatMediatingC-Reactive ProteinHormonesMuscle FormGrowth Hormone DeficiencyFundingRisk FactorsMenopauseRelative (Related Person)

Grant awards (76)

CTSA K12 Program at Harvard Medical School$1,619,800
K12 · FY2025 · TR · contact PI
Training Program in Endocrinology$989,948
T32 · FY2025 · DK · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2025 · DK · contact PI
Romosozumab as an adjunct to physiologic estrogen replacement in adolescents and young adults with functional hypothalamic amenorrhea$608,114
R01 · FY2025 · HD · contact PI
Training Program in Endocrinology$39,221
T32 · FY2025 · DK · contact PI
CTSA K12 Program at Harvard Medical School$1,619,800
K12 · FY2024 · TR · contact PI
Training Program in Endocrinology$921,056
T32 · FY2024 · DK · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$704,322
R01 · FY2024 · DK · contact PI
Romosozumab as an adjunct to physiologic estrogen replacement in adolescents and young adults with functional hypothalamic amenorrhea$624,864
R01 · FY2024 · HD · contact PI
Training Program in Endocrinology$97,637
T32 · FY2024 · DK · contact PI
CTSA K12 Program at Harvard Medical School$1,619,800
K12 · FY2023 · TR · contact PI
Training Program in Endocrinology$842,446
T32 · FY2023 · DK · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2023 · DK · contact PI
Training Program in Endocrinology$90,998
T32 · FY2023 · DK · contact PI
Training Program in Endocrinology$868,777
T32 · FY2022 · DK · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2022 · DK · contact PI
Training Program in Endocrinology$88,564
T32 · FY2022 · DK · contact PI
Training Program in Endocrinology$787,075
T32 · FY2021 · DK · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2021 · DK · contact PI
Training Program in Endocrinology$82,107
T32 · FY2021 · DK · contact PI
Training Program in Endocrinology$794,513
T32 · FY2020 · DK · contact PI
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism, and Energy Balance$1,573,788
R24 · FY2019 · DK
Training Program in Endocrinology$751,004
T32 · FY2019 · DK · contact PI
Growth Hormone and Cardiovascular Disease$120,647
K24 · FY2019 · HL · contact PI
Training Program in Endocrinology$710,344
T32 · FY2018 · DK · contact PI
Growth Hormone and Cardiovascular Disease$120,647
K24 · FY2018 · HL · contact PI
Training Program in Endocrinology$702,878
T32 · FY2017 · DK · contact PI
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone$634,523
R01 · FY2017 · DK · contact PI
Growth Hormone and Cardiovascular Disease$120,647
K24 · FY2017 · HL · contact PI
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone$637,794
R01 · FY2016 · DK · contact PI
Growth Hormone and Cardiovascular Disease$120,647
K24 · FY2016 · HL · contact PI
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone$637,794
R01 · FY2015 · DK · contact PI
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2015 · MH · contact PI
Growth Hormone and Cardiovascular Disease$120,647
K24 · FY2015 · HL · contact PI
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone$637,794
R01 · FY2014 · DK · contact PI
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2014 · MH · contact PI
Growth Hormone and Cardiovascular Disease$198,311
K24 · FY2014 · HL · contact PI
Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone$658,239
R01 · FY2013 · DK · contact PI
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2013 · MH · contact PI
Growth Hormone and Cardiovascular Disease$199,733
K24 · FY2013 · HL · contact PI
Growth Hormone and Cardiovascular Disease$201,115
K24 · FY2012 · HL · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$614,027
R01 · FY2011 · HL · contact PI
Growth Hormone and Cardiovascular Disease$202,457
K24 · FY2011 · HL · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$620,782
R01 · FY2010 · HL · contact PI
Growth Hormone and Cardiovascular Disease$198,294
K24 · FY2010 · HL · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$601,724
R01 · FY2009 · HL · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$166,830
R01 · FY2009 · HL · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$583,805
R01 · FY2008 · HL · contact PI
CLINICAL TRIAL: GH CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY$16,189
M01 · FY2008 · RR · contact PI
GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$2,267
M01 · FY2008 · RR · contact PI
GH, Cardiovascular Risk and Visceral Adiposity in Women$585,868
R01 · FY2007 · HL · contact PI
GH CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$34,399
M01 · FY2007 · RR · contact PI
GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$13,502
M01 · FY2007 · RR · contact PI
GH CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$117,050
M01 · FY2006 · RR · contact PI
GH, CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$19,714
M01 · FY2006 · RR · contact PI
GH CARDIOVASCULAR RISK AND VISCERAL ADIPOSITY IN WOMEN$478
M01 · FY2005 · RR
Dietary Fat Effects on Leptin and Menstrual Function$200,768
M01 · FY2002 · RR
Dietary Fat Effects on Leptin and Menstrual Function$200,768
M01 · FY2002 · RR
Androgen Deficiency in Women with Hypopituitarism$200,768
M01 · FY2002 · RR
Androgen Deficiency in Women with Hypopituitarism$200,768
M01 · FY2002 · RR
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$200,768
M01 · FY2002 · RR
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$200,768
M01 · FY2002 · RR
Androgen Deficiency and Osteopenia in Anorexia Nervosa$86,500
R03 · FY2002 · DK
Dietary Fat Effects on Leptin and Menstrual Function$200,768
M01 · FY2001 · RR
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$200,768
M01 · FY2001 · RR
Androgen Deficiency in Women with Hypopituitarism$200,768
M01 · FY2001 · RR
Androgen Deficiency and Osteopenia in Anorexia Nervosa$86,500
R03 · FY2001 · DK
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$0
M01 · FY2001 · RR
Androgen Deficiency in Women with Hypopituitarism$0
M01 · FY2001 · RR
Dietary Fat Effects on Leptin and Menstrual Function$0
M01 · FY2001 · RR
Dietary Fat Effects on Leptin and Menstrual Function$0
M01 · FY2000 · RR
Androgen Deficiency in Women with Hypopituitarism$0
M01 · FY2000 · RR
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$0
M01 · FY2000 · RR
ORTHO TRI CYCLEN ON BIOCHEM MARKERS OF BONE METAB IN HYPOTHALAMIC AMENORRHEA$0
M01 · FY2000 · RR
Dietary Fat Effects on Leptin and Menstrual Function$0
M01 · FY2000 · RR
Androgen Deficiency in Women with Hypopituitarism$0
M01 · FY2000 · RR